UVDI Announces UV-C Device Presentations at the 16th World Congress on Public Health 2020
Ultraviolet Devices, Inc. (UVDI), a global leader in UV-C surface disinfecting and indoor air quality products, today announced its first Italian hospital studies demonstrating the advanced effectiveness of the UVDI-360 Room Sanitizer will be presented at the 16th World Congress on Public Health 2020, taking place October 12 – 16, 2020. The novel research, conducted by Dr. Gabriele Messina, Associate Professor of Public Health, University of Siena, at the Rugani Hospital Monteriggioni in Siena, demonstrates the UVDI-360’s ability to inactivate pathogens in the hospital environment as part of varied cleaning protocols, in multiple high-risk locations and at different disinfecting cycle times.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005076/en/
Researchers from the University of Siena will present "Six ultraviolet minutes for cleaner operating theatres" at the 16th World Congress on Public Health 2020. (Photo: Business Wire)
Presentations from Dr. Messina and his Team at the University of Siena include:
(1) one poster sharing preliminary data of a cross-sectional study measuring overall pathogen reduction on high-touch surfaces in hospital rooms pre-and-post use of the UVDI-360 Room Sanitizer as a supplement to terminal cleaning. Preliminary findings conclude 83% of sites sampled had 0 CFU following the use of the UVDI-360 Room Sanitizer.
(2) a second poster sharing preliminary data of a cross-sectional study demonstrating overall pathogen reduction in operating rooms in six minutes with the UVDI-360 Room Sanitizer used in multiple protocols: with no manual cleaning, manual cleaning in-between operating room use and as a supplement to manual terminal cleaning.
(3) an oral presentation sharing research demonstrating 3-and-4-log reductions of Candida auris at 2.44 meters using the UVDI-360 Room Sanitizer.
(4) a third poster illustrating a simulation model of microbe distribution on surfaces to inform future UV-C testing.
Title:
Six ultraviolet minutes for cleaner operating theatres
Track: Health Technology Assessment
Abstract: #DJ-15
Title: Analytical approach for a better control of environmental contamination
Track: Hospital hygiene (including AMR), healthcare-associated infections (HAI)
Abstract: #DN-18
Title:
A simulation model of microbe overlapping for the correct estimation of UV-C device log-reduction
Track: Healthcare Technology Assessment
Abstract: #DJ-14
Oral Presentation:
Tuning a UV-C device to challenge new threats in the sanitization setting of healthcare facilities
Date and Time: October 13th, 12:15-13:15
Poster abstracts are accessible via the World Congress website, https://wcph2020.com/. The poster presentations may be accessed through UVDI’s website following their presentation.
About UVDI
UVDI's Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. Founded in 1949 by Louis Veloz, UVDI designs and makes next-generation germicidal Ultraviolet light solutions in California applying over 70 years and three generations of family craftsmanship and care. The UVDI-360 Room Sanitizer is now used globally in over 25 countries in the world’s leading hospitals, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate the highest-risk pathogens. UVDI is proud to be a certified Minority Business Enterprise (MBE).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201011005076/en/
Contact information
Media Contact | UVDI
Will Gerard
Director of Marketing
661. 289. 2741
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
